Most prostate cancers are slow growing. The majority of men diagnosed have a low-grade form that may take years or even decades to cause any symptoms, and many will never need treatment at all. But “prostate cancer” is not one disease. A small percentage of cases are aggressive, fast-moving, and potentially lethal. The difference between the two comes down to the cancer’s grade, and understanding where yours falls on that spectrum is the single most important factor in determining what happens next.
How Slow Is “Slow Growing”?
Prostate cancer’s reputation as a slow cancer is well earned by the numbers. The 10-year relative survival rate across all stages is 98%, meaning the average man with prostate cancer is only 2% less likely to be alive a decade later than a man without it. At 15 years, that gap widens only slightly to 5%. These figures, from Johns Hopkins Medicine, include every stage and grade of the disease, so for men with localized, low-grade cancer, the outlook is even better.
One way researchers measure how fast a cancer grows is by tracking how quickly a tumor marker in the blood (PSA) doubles after treatment. Men whose PSA takes years to double tend to have indolent, slow-moving disease. Men whose PSA doubles in under six months have the most aggressive tumors and face the highest risk of dying from their cancer. For many low-grade prostate cancers, that doubling time stretches well beyond a year.
Screening studies help put the timeline in perspective. Research published in the Journal of the National Cancer Institute estimated that PSA screening detects prostate cancer an average of 11 to 12 years before it would have caused symptoms on its own. For a man screened at age 55, that lead time averaged 12.3 years. Even at age 75, cancer was caught roughly 6 years before it would have become noticeable. That gap tells you something important: many of these cancers sit quietly in the prostate for over a decade without doing anything harmful.
What Determines How Fast It Grows
The grade of the cancer is the key predictor. When a biopsy sample is examined under a microscope, a pathologist assigns a Gleason score based on how abnormal the cells look and how they’re arranged. This score ranges from 6 to 10 and directly reflects how quickly the cancer is likely to grow and spread.
- Gleason 6 (Grade Group 1): The lowest and least serious grade. These cancer cells grow slowly and are unlikely to spread. This is the most commonly diagnosed grade, and many men with a Gleason 6 cancer will never need surgery or radiation.
- Gleason 7 (Grade Groups 2 and 3): An intermediate grade. A score of 3+4 leans closer to low risk, while 4+3 tilts toward more aggressive behavior, because grade 4 cells grow faster and are less organized than grade 3 cells.
- Gleason 8 to 10 (Grade Groups 4 and 5): High-grade cancer. The cells have lost normal structure, often forming large, disorganized masses. These cancers grow quickly and carry a higher risk of spreading to the bones, lymph nodes, or other organs.
Your Gleason score, combined with your PSA level and the stage of the tumor, determines whether your cancer is classified as low, intermediate, or high risk. That risk category shapes every treatment decision that follows.
Active Surveillance for Low-Risk Cancer
Because so many prostate cancers grow slowly, doctors now routinely recommend a strategy called active surveillance for men with low-grade disease. Rather than immediately treating the cancer with surgery or radiation, you’re monitored closely with regular PSA blood tests, periodic biopsies, and sometimes MRI scans. The goal is to avoid the side effects of treatment (urinary incontinence, erectile dysfunction) unless the cancer shows signs of becoming more aggressive.
This is not the same as ignoring the cancer. Active surveillance involves a structured schedule of checkups, and if a follow-up biopsy shows the grade has increased or the tumor is growing, treatment begins. For men with Gleason 6 cancer, studies consistently show that delaying treatment through active surveillance does not reduce long-term survival. Many men remain on surveillance for years, and some never need treatment at all.
When Prostate Cancer Is Not Slow Growing
Roughly 15% to 20% of prostate cancers are high-grade at diagnosis, and these behave very differently. High-grade tumors can grow rapidly, invade surrounding tissues, and metastasize to distant parts of the body. For these men, prompt treatment is critical.
There is also a rare but particularly aggressive subtype worth knowing about. Some prostate cancers, after being treated with hormone-blocking therapies, transform into a subtype called small-cell neuroendocrine prostate cancer. These tumors look completely different under a microscope: the cells are smaller, more densely packed, and driven by different genetic mutations. Men with this subtype have a median survival of about 36 to 37 months after metastasis, compared to roughly 44.5 months for the more common form. This subtype doesn’t always show up on standard PSA tests, which can make it harder to detect. It’s uncommon, but it underscores the point that not all prostate cancers follow the slow-growing pattern.
Why Overdiagnosis Matters
The fact that most prostate cancers grow slowly creates a real medical dilemma. Screening catches many cancers that would never have caused harm during a man’s lifetime. When screening detects a cancer 12 years before it would have produced symptoms in a 55-year-old, that’s valuable if the cancer turns out to be aggressive. But if it’s a Gleason 6 that would have stayed quiet for decades, the diagnosis itself can lead to unnecessary anxiety, biopsies, and treatments with lasting side effects.
This is why screening guidelines have shifted over the years. Rather than recommending routine PSA testing for all men, most medical organizations now recommend that men discuss the pros and cons with their doctor and make an individual decision based on age, family history, and risk factors. For men with a strong family history of prostate cancer or who are Black (a group with higher rates of aggressive prostate cancer), the conversation typically starts earlier, around age 40 to 45.
What This Means in Practice
If you’ve just been told you have prostate cancer, the natural instinct is urgency. But for the majority of men, particularly those with low-grade, localized disease, time is on your side. You have weeks, not days, to understand your diagnosis, get a second opinion on your biopsy, and weigh your options carefully. The 15-year survival rate of 95% across all stages reflects a disease that, in most cases, progresses slowly enough to manage effectively.
The critical step is confirming your cancer’s grade. A Gleason 6 cancer and a Gleason 9 cancer share a name but behave like entirely different diseases. Once you know your grade and stage, the path forward becomes much clearer: watchful monitoring for slow growers, prompt treatment for aggressive ones.